Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Taysha Gene Therapies (Nasdaq: TSHA) regained full global rights to its lead TSHA-102 Rett syndrome program after the 2022 Option Agreement with Astellas expired on Oct 16, 2025. TSHA-102 previously received FDA Breakthrough Therapy designation based on Part A REVEAL data (May 2025 cutoff) showing a generally well-tolerated safety profile and a 100% response rate on the pivotal trial primary endpoint.

First patient dosing in the REVEAL pivotal trial is scheduled this quarter; the single-arm trial will evaluate a 1x10^15 vg intrathecal dose in 15 females aged 6–<22, with a 6-month interim analysis that may support a BLA.

Taysha Gene Therapies (NASDAQ: TSHA) reported a supplemental analysis from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome on October 9, 2025. The analysis found a previously disclosed 100% response rate (N=10) for the primary endpoint of gain/regain of ≥1 natural‑history developmental milestone, with a total of 22 milestones achieved. Structured, validated scales showed 165 additional skills/improvements across communication, fine motor, gross motor and autonomic domains. Data reflect Part A high dose (1x10^15 vg; N=6) and low dose (5.7x10^14 vg; N=4) with a May 2025 cutoff. Poster and figures available on the company website.

Taysha Gene Therapies (Nasdaq: TSHA) announced that on October 1, 2025 its Compensation Committee granted inducement stock options to seven new employees totaling 1,289,600 shares under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $3.18 (equal to the closing price on the grant date), a 10-year term, and vest over four years (25% after one year, then monthly ratable vesting over 36 months), subject to continued service.

Taysha Gene Therapies (NASDAQ:TSHA) has received FDA Breakthrough Therapy designation for TSHA-102, its gene therapy treatment for Rett syndrome. The designation was granted based on clinical evidence from 12 patients in Part A of the REVEAL Phase 1/2 trials, showing a 100% response rate in developmental milestone achievement.

The company has also finalized FDA alignment on the REVEAL pivotal trial protocol and statistical analysis plan. Key elements include a 6-month interim analysis that could expedite BLA submission. The pivotal trial will evaluate 15 female patients aged 6-22 years, with a minimum success threshold of 33% response rate. Patient enrollment is scheduled to begin in Q4 2025.

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted stock options to five new employees. The Compensation Committee approved options to purchase 225,000 shares at an exercise price of $2.84 per share under the company's 2023 Inducement Plan.

The options have a 10-year term with a four-year vesting schedule: 25% vests after one year, followed by monthly vesting over 36 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Taysha Gene Therapies (NASDAQ: TSHA) reported significant progress in Q2 2025, highlighted by the commencement of site activation for their REVEAL pivotal trial for TSHA-102 in Rett syndrome treatment. The trial follows successful Phase 1/2 results showing a 100% response rate for the primary endpoint of developmental milestone gains.

The company significantly strengthened its financial position through a $230 million public offering, extending their cash runway into 2028. As of June 30, 2025, Taysha held $312.8 million in cash. Q2 2025 saw a net loss of $26.9 million ($0.09 per share), compared to $20.9 million in Q2 2024.

The REVEAL pivotal trial will enroll 15 females aged 6-22 years with Rett syndrome, with patient enrollment expected to begin in Q4 2025. Importantly, both high and low doses of TSHA-102 have shown favorable safety profiles with no treatment-related SAEs in 12 patients treated.

Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET. The company will present its financial performance for the quarter ended June 30, 2025, along with a corporate update.

Investors can access the call via toll-free number (877-407-0792) or international line (201-689-8263) using conference ID 13754869. A webcast will also be available on the company's investor relations website.

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted a stock option to a new employee. The inducement grant includes options to purchase 90,000 shares at an exercise price of $2.63 per share under the company's 2023 Inducement Plan.

The stock option has a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.

Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted stock options to two new employees. The Compensation Committee approved options to purchase 30,000 shares of common stock at an exercise price of $2.34 per share under the company's 2023 Inducement Plan.

The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.